Effects of Processing and Storage Conditions on Amyloid β (1–42) and Tau Concentrations in Cerebrospinal Fluid: Implications for Use in Clinical Practice
- 1 January 2005
- journal article
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 51 (1) , 189-195
- https://doi.org/10.1373/clinchem.2004.039735
Abstract
Reported concentrations of amyloid beta (1-42) (A beta 42) and tau in cerebrospinal fluid (CSF) differ among reports. We investigated the effects of storage temperature, repeated freeze/thaw cycles, and centrifugation on the concentrations of A beta 42 and tau in CSF. Stability of samples stored at -80 degrees C was determined by use of an accelerated stability testing protocol according to the Arrhenius equation. A beta 42 and tau concentrations were measured in CSF samples stored at 4, 18, 37, and -80 degrees C. Relative CSF concentrations (%) of the biomarkers after one freeze/thaw cycle were compared with those after two, three, four, five, and six freeze/thaw cycles. In addition, relative A beta 42 and tau concentrations in samples not centrifuged were compared with samples centrifuged after 1, 4, 48, and 72 h. A beta 42 and tau concentrations were stable in CSF when stored for a long period at -80 degrees C. CSF A beta 42 decreased by 20% during the first 2 days at 4, 18, and 37 degrees C compared with -80 degrees C. CSF tau decreased after storage for 12 days at 37 degrees C. After three freeze/thaw cycles, CSF A beta 42 decreased 20%. CSF tau was stable during six freeze/thaw cycles. Centrifugation did not influence the biomarker concentrations. Repeated freeze/thaw cycles and storage at 4, 18, and 37 degrees C influence the quantitative result of the A beta 42 test. Preferably, samples should be stored at -80 degrees C immediately after collection.Keywords
Funding Information
- Alzheimer Nederland (V2001-023)
- Stichting Alzheimer
- Neuropsychiatry Foundation
This publication has 21 references indexed in Scilit:
- Amyloid β(1–42) and phosphorylated tau in CSF as markers for early-onset Alzheimer diseaseNeurology, 2004
- CSF markers for incipient Alzheimer's diseaseThe Lancet Neurology, 2003
- Decreased β-Amyloid1-42and Increased Tau Levels in Cerebrospinal Fluid of Patients With Alzheimer DiseaseJAMA, 2003
- STABILITY OF INTERLEUKIN 6, SOLUBLE INTERLEUKIN 6 RECEPTOR, INTERLEUKIN 10 AND CC16 IN HUMAN SERUMCytokine, 2002
- Evaluation of CSF-tau and CSF-Aβ42 as Diagnostic Markers for Alzheimer Disease in Clinical PracticeArchives of Neurology, 2001
- Quantification of Alzheimer Amyloid β Peptides Ending at Residues 40 and 42 by Novel ELISA SystemsMolecular Medicine, 2000
- Standardization of measurement of β-amyloid(1-42)in cerebrospinal fluid and plasmaAmyloid, 2000
- Improved discrimination of AD patients using β-amyloid (1-42) and tau levels in CSFNeurology, 1999
- Detection of Proteins in Normal and Alzheimer's Disease Cerebrospinal Fluid with a Sensitive Sandwich Enzyme‐Linked Immunosorbent AssayJournal of Neurochemistry, 1993
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984